A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy.
Adolescent
Antineoplastic Agents, Phytogenic
/ adverse effects
Child
Child, Preschool
Early Diagnosis
Female
Humans
Male
Metabolomics
/ methods
Peripheral Nervous System Diseases
/ chemically induced
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
User-Computer Interface
Vincristine
/ adverse effects
Workflow
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
received:
05
12
2019
accepted:
26
04
2020
entrez:
17
6
2020
pubmed:
17
6
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Vincristine is a core chemotherapeutic drug administered to pediatric acute lymphoblastic leukemia patients. Despite its efficacy in treating leukemia, it can lead to severe peripheral neuropathy in a subgroup of the patients. Peripheral neuropathy is a debilitating and painful side-effect that can severely impact an individual's quality of life. Currently, there are no established predictors of peripheral neuropathy incidence during the early stage of chemotherapeutic treatment. As a result, patients who are not susceptible to peripheral neuropathy may receive sub-therapeutic treatment due to an empirical upper cap on the dose, while others may experience severe neuropathy at the same dose. Contrary to previous genomics based approaches, we employed a metabolomics approach to identify small sets of metabolites that can be used to predict a patient's susceptibility to peripheral neuropathy at different time points during the treatment. Using those identified metabolites, we developed a novel strategy to predict peripheral neuropathy and subsequently adjust the vincristine dose accordingly. In accordance with this novel strategy, we created a free user-friendly tool, VIPNp, for physicians to easily implement our prediction strategy. Our results showed that focusing on metabolites, which encompasses both genotypic and phenotypic variations, can enable early prediction of peripheral neuropathy in pediatric leukemia patients.
Identifiants
pubmed: 32541868
doi: 10.1038/s41598-020-66815-y
pii: 10.1038/s41598-020-66815-y
pmc: PMC7295796
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Vincristine
5J49Q6B70F
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
9659Subventions
Organisme : NIH HHS
ID : UL1TR002529
Pays : United States
Organisme : NICHD NIH HHS
ID : R01HD062484-06
Pays : United States
Références
Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescent cancer statistics, 2014. CA: a cancer journal for clinicians 64, 83–103 (2014).
American Cancer Society, Cancer Facts & Figures 2018, https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html (Accessed: 04-08-2019).
Mora, E., Smith, E. M. L., Donohoe, C. & Hertz, D. L. Vincristine-induced peripheral neuropathy in pediatric cancer patients. American journal of cancer research 6, 2416 (2016).
pubmed: 27904761
pmcid: 5126263
van de Velde, M. E. et al. Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. Critical reviews in oncology/hematology 114, 114–130 (2017).
doi: 10.1016/j.critrevonc.2017.04.004
Lavoie Smith, E. M. et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Journal of the Peripheral Nervous System 20, 37–46 (2015).
doi: 10.1111/jns.12114
Lehtinen, S. S. et al. Motor nervous system impairment persists in long-term survivors of childhood acute lymphoblastic leukemia. Cancer: Interdisciplinary International Journal of the American Cancer Society 94, 2466–2473 (2002).
doi: 10.1002/cncr.10503
Ness, K. K. et al. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer 118, 828–838 (2012).
doi: 10.1002/cncr.26337
Reinders-Messelink, H. A. et al. Fine motor and handwriting problems after treatment for childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology 27, 551–555 (1996).
doi: 10.1002/(SICI)1096-911X(199612)27:6<551::AID-MPO8>3.0.CO;2-K
De Luca, C. R. et al. Gross and fine motor skills in children treated for acute lymphoblastic leukaemia. Developmental neurorehabilitation 16, 180–187 (2013).
doi: 10.3109/17518423.2013.771221
Ness, K. K. et al. Limitations on physical performance and daily activities among long-term survivors of childhood cancer. Annals of internal medicine 143, 639–647 (2005).
doi: 10.7326/0003-4819-143-9-200511010-00007
Anghelescu, D. L. et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer 57, 1147–1153, https://doi.org/10.1002/pbc.23039 (2011).
doi: 10.1002/pbc.23039
Diouf, B. et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. Jama 313, 815–823 (2015).
doi: 10.1001/jama.2015.0894
Kishi, S. et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109, 4151–4157, https://doi.org/10.1182/blood-2006-10-054528 , http://www.bloodjournal.org/content/109/10/4151.full.pdf (2007).
Renbarger, J. L., McCammack, K. C., Rouse, C. E. & Hall, S. D. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatric blood & cancer 50, 769–771 (2008).
doi: 10.1002/pbc.21435
Moore, A. S. et al. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach. Journal of Paediatrics and Child Health 47, 875–882, https://doi.org/10.1111/j.1440-1754.2011.02103.x (2011).
doi: 10.1111/j.1440-1754.2011.02103.x
pubmed: 21658147
Aplenc, R. et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. British journal of haematology 122, 240–244 (2003).
doi: 10.1046/j.1365-2141.2003.04430.x
Egbelakin, A. et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer 56, 361–367, https://doi.org/10.1002/pbc.22845 (2011).
doi: 10.1002/pbc.22845
Guilhaumou, R. et al. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer chemotherapy and pharmacology 68, 1633–1638 (2011).
doi: 10.1007/s00280-011-1745-2
Ceppi, F. et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 15, 1105–1116, https://doi.org/10.2217/pgs.14.68 , PMID: 25084203 (2014).
Lopez-Lopez, E. et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics 17, 731–741, https://doi.org/10.2217/pgs-2016-0001 , PMID: 27180762 (2016).
Groninger, E. et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatric Research 52, 113 (2002).
doi: 10.1203/00006450-200207000-00021
Crom, W. R. et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. The Journal of pediatrics 125, 642–649 (1994).
doi: 10.1016/S0022-3476(94)70027-3
Gidding, C. et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer chemotherapy and pharmacology 44, 203–209 (1999).
doi: 10.1007/s002800050968
Van den Berg, H. et al. The pharmacokinetics of vincristine in man. Cancer chemotherapy and pharmacology 8, 215–219 (1982).
doi: 10.1007/BF00255487
Gidding, C., Kellie, S., Kamps, W. & De Graaf, S. Vincristine revisited. Critical reviews in oncology/hematology 29, 267–287 (1999).
doi: 10.1016/S1040-8428(98)00023-7
Stock, W. et al. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clinical Pharmacology & Therapeutics 101, 391–395, https://doi.org/10.1002/cpt.506 (2017).
doi: 10.1002/cpt.506
Wright, G. E. et al. Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. Clinical Pharmacology & Therapeutics 105, 402–410, https://doi.org/10.1002/cpt.1179 (2019).
doi: 10.1002/cpt.1179
Gutierrez-Camino, A. et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenetics and genomics 26, 100–102 (2016).
doi: 10.1097/FPC.0000000000000191
Diouf, B. & Evans, W. E. Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues. Clinical Pharmacology & Therapeutics 105, 315–317, https://doi.org/10.1002/cpt.1209 (2019).
doi: 10.1002/cpt.1209
Jayachandran, D., Ramkrishna, U., Skiles, J., Renbarger, J. & Ramkrishna, D. Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression. CPT: pharmacometrics & systems pharmacology 3, 1–11 (2014).
Kaddurah-Daouk, R., Weinshilboum, R. & on behalf of the Pharmacometabolomics Research Network. Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. Clinical Pharmacology & Therapeutics 98, 71–75, https://doi.org/10.1002/cpt.134 (2015).
Li, B., He, X., Jia, W. & Li, H. Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review. Molecules 22, https://doi.org/10.3390/molecules22071173 (2017).
VIPNp. https://parulv1.shinyapps.io/vipnp_shiny/ .
VIPNp. https://github.com/parulv1/VIPNp .
Smith, E. M. L. et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer nursing 36, E49 (2013).
doi: 10.1097/NCC.0b013e318299ad23
Chen, S. & Bowman, F. D. A novel support vector classifier for longitudinal high-dimensional data and its application to neuroimaging data. Statistical Analysis and Data Mining: The ASA Data Science Journal 4, 604–611 (2011).
doi: 10.1002/sam.10141
Smith, C. A. et al. METLIN: a metabolite mass spectral database. Therapeutic drug monitoring 27, 747–751 (2005).
doi: 10.1097/01.ftd.0000179845.53213.39
Wishart, D. S. et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Research 46, D608–D617, https://doi.org/10.1093/nar/gkx1089 , http://oup.prod.sis.lan/nar/article-pdf/46/D1/D608/23162277/gkx1089.pdf (2017).
de la Fuente, A. G. et al. Knowledge-based metabolite annotation tool: CEU Mass Mediator. Journal of pharmaceutical and biomedical analysis 154, 138–149 (2018).
doi: 10.1016/j.jpba.2018.02.046
Gil-de-la Fuente, A. et al. CEU Mass Mediator 3.0: a metabolite annotation tool. Journal of proteome research 18, 797–802 (2018).
doi: 10.1021/acs.jproteome.8b00720
Chong, J. & Xia, J. MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics 34, 4313–4314 (2018).
doi: 10.1093/bioinformatics/bty528
Chong, J. et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic acids research 46, W486–W494 (2018).
doi: 10.1093/nar/gky310
Janes, K. et al. The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. Journal of Biological Chemistry 289, 21082–21097 (2014).
doi: 10.1074/jbc.M114.569574
Kramer, R. et al. Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. The FASEB Journal 29, 4461–4472 (2015).
doi: 10.1096/fj.15-272567
Stockstill, K. et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. Journal of Experimental Medicine 215, 1301–1313 (2018).
doi: 10.1084/jem.20170584
Starobova, H. & Vetter, I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Frontiers in molecular neuroscience 10, 174 (2017).
doi: 10.3389/fnmol.2017.00174
Wu, F.-Z. et al. Wen-Luo-Tong Decoction Attenuates Paclitaxel-Induced Peripheral Neuropathy by Regulating Linoleic Acid and Glycerophospholipid Metabolism Pathways. Frontiers in pharmacology 9 (2018).
Chen, E. I. et al. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS One 10, 1–15, https://doi.org/10.1371/journal.pone.0145816 (2016).
doi: 10.1371/journal.pone.0145816
Li, L. et al. Genetic variants associated with vincristine-induced peripheral neuropathy in two populations of children with acute lymphoblastic leukemia. Clinical Pharmacology & Therapeutics 105, 1421–1428, https://doi.org/10.1002/cpt.1324 (2019).
doi: 10.1002/cpt.1324
Adamson, S. X.-F., Wang, R., Wu, W., Cooper, B. & Shannahan, J. Metabolomic insights of macrophage responses to graphene nanoplatelets: Role of scavenger receptor cd36. PLoS One 13, 1–30, https://doi.org/10.1371/journal.pone.0207042 (2018).
doi: 10.1371/journal.pone.0207042
Yang, F., Wang, H., Liu, M., Hu, P. & Jiang, J. Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography A 1275, 61–69, https://doi.org/10.1016/j.chroma.2012.12.026 (2013).
doi: 10.1016/j.chroma.2012.12.026
pubmed: 23294995
R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2017).
Armitage, E. G., Godzien, J., Alonso-Herranz, V., López-Gonzálvez, Á. & Barbas, C. Missing value imputation strategies for metabolomics data. Electrophoresis 36, 3050–3060 (2015).
doi: 10.1002/elps.201500352
Hastie, T., Tibshirani, R., Narasimhan, B. & Chu, G. Impute: Imputation for microarray data, R package version 1.50.1 (2017).
from Jed Wing, M. K. C. et al. caret: Classification and Regression Training. R package version 6.0-78.
Meyer, D., Dimitriadou, E., Hornik, K., Weingessel, A. & Leisch, F. e1071: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: E1071), TU Wien, R package version 1.6-8 (2017).